| Literature DB >> 29452161 |
Carolina E Vaisman1, Oscar Del Moral-Hernandez2, Samadhi Moreno-Campuzano1, Elena Aréchaga-Ocampo3, Raul Bonilla-Moreno1, Israel Garcia-Aguiar1, Leticia Cedillo-Barron1, Jaime Berumen4, Porfirio Nava5, Nicolas Villegas-Sepúlveda6.
Abstract
The HPV-16 E6/E7 bicistronic immature transcript produces 4 mature RNAs: the unspliced HPV-16 E6/E7pre-mRNA product and 3 alternatively spliced mRNAs. The 3 spliced mRNAs encode short forms of the E6 oncoprotein, namely E6*I, E6*II and E6^E7. In this study we showed that transfection of C-33A cells with monocistronic constructs of these cDNAs fused to GFP, produced different effects on apoptosis, after the treatment with cisplatin. Transfection of C-33A cells with the full-length E6-GFP oncoprotein resulted in a 50% decrease in cell death, while the transfection with the E6*I-GFP construct showed only a 25% of diminution of cell death, compared to the control cells. Transfection with the E6^E7-GFP or E7-GFP construct had no effect on the number of the apoptotic cells, compared with control cells. Conversely, transfection with the E6*II construct resulted in higher cell death than the control cells. Taken together, these results suggested that E6*I or E6*II, the short forms of HPV-16 E6, displayed opposite effects on cisplatin-induced apoptosis, when transfected in C-33A cells.Entities:
Keywords: Apoptosis resistance; Cisplatin; E6 splice donor mutant; E6 spliced forms; HPV16 E6; Transfected C-33A cells
Mesh:
Substances:
Year: 2018 PMID: 29452161 DOI: 10.1016/j.virusres.2018.02.009
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303